No Data
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases
This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Express News | Wedbush Initiates Coverage On Zura Bio With Outperform Rating, Announces Price Target of $15
Zura Bio Analyst Ratings
Wedbush Initiates Zura Bio(ZURA.US) With Buy Rating, Announces Target Price $15